Qiagen

Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

PDF page sample
Pages
65
Language
English
Published on
06/02/25
Download
You may also be interested by these reports :
14/07/26
Dräger delivered a strong set of Q2 2026 preliminary figures, with both revenue and earnings ahead of consensus. The guidance upgrade on the EBIT ...
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not  helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO